Document Detail


Ezetimbe as potential treatment for cholesterol gallstones: the need for clinical trials.
MedLine Citation:
PMID:  20355232     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Obesity is associated with insulin resistance, non-alcoholic fatty liver disease (NAFLD) and gallstones.High fat diets (unsaturated fats) rich in cholesterol have been demonstrated to produce not only gallstones but also NAFLD and insulin resistance. Interestingly, a high incidence of gallstones is being reported in association with insulin resistance and NAFLD. Laparoscopic cholecystectomy is the best definitive therapy for symptomatic gallbladder disease. Ezetimibe is a drug that inhibits the absorption of both dietary and biliary cholesterol in the small intestine. Importantly, ezetimibe showed potential benefit not only in treating and preventing gallstones but also in insulin resistance and NAFLD. Further studies are required before the use of ezetimibe for the treatment of gallstones can be advocated.
Authors:
Mohamed H Ahmed
Publication Detail:
Type:  Editorial    
Journal Detail:
Title:  World journal of gastroenterology : WJG     Volume:  16     ISSN:  1007-9327     ISO Abbreviation:  World J. Gastroenterol.     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-03-31     Completed Date:  2010-07-29     Revised Date:  2010-09-28    
Medline Journal Info:
Nlm Unique ID:  100883448     Medline TA:  World J Gastroenterol     Country:  China    
Other Details:
Languages:  eng     Pagination:  1555-7     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Anticholesteremic Agents / therapeutic use*
Azetidines / therapeutic use*
Cholesterol / metabolism*
Clinical Trials as Topic
Diet
Drug Evaluation, Preclinical / methods
Fatty Liver / drug therapy
Gallstones / drug therapy*
Humans
Insulin Resistance
Intestine, Small / drug effects
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Azetidines; 163222-33-1/ezetimibe; 57-88-5/Cholesterol
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Nanoparticle technology: amplifying the effective sensitivity of biomarker detection to create a uri...
Next Document:  Liver fat content determined by magnetic resonance imaging and spectroscopy.